12.6.04FibroGen Reports Phase 1 Results of Investigational Oral Anemia Therapy, FG-2216, and New Data from Phase 2A Study in Anemic Chronic Kidney Disease Patients
11.1.04FibroGen Announces FG-3019 Improves Kidney Function in a Late-Stage Disease Model of Diabetic Nephropathy
11.1.04FibroGen Investigational Small Molecule Anemia Therapy, FG-2216, Increased Endogenous EPO Production in Humans
10.27.04FibroGen Announces FG-3019 Found Safe and Well Tolerated in Patients with Idiopathic Pulmonary Fibrosis
9.24.04FibroGen Enters Agreement with Yamanouchi to License Erythropoietic Small Molecule in Development for the Treatment of Anemia
4.1.04FibroGen Announces Three Scientific Publications Highlighting Important Medical Device and Pharmaceutical Uses of Recombinant Human Collagens and Gelatins
3.25.04FibroGen Reports Advances in Targeting Hypoxia-Inducible Factor (HIF) for Drug Development
